Showing 211-220 of 295 results for "".
- FDA Nod for Sientra’s Low Plus Profile Projection Breast Implanthttps://modernaesthetics.com/news/fda-nod-for-sientras-low-plus-profile-projection-breast-implant-1/2473263/The U.S. Food and Drug Administration (FDA) approved Sientra’s Low Plus Profile Projection Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction. This product will be commercially available for board-certi
- Cynosure Rolls Out PicoSure Pro Devicehttps://modernaesthetics.com/news/cynosure-rolls-out-picosure-pro-device/2473248/Cynosure is launching the PicoSure Pro device, the latest upgrade to the company's PicoSure system. The FDA-cleared 755nm picosecond laser on the market, the PicoSure Pro device uniquely delivers energy in a trillionth of a second, utilizing pressure instead of heat to provide
- Rion Aesthetics Initiates Series Ahttps://modernaesthetics.com/news/rion-aesthetics-initiates-series-a/2473241/With the initiation of Series A funding, Rion Aesthetics presents a unique investment opportunity for aesthetic providers. Rion plans on closing the Series A in the second quarter of 2022. Rion, a regenerati
- Endymed's US Subsidiary Taps Bill Scott as New Presidenthttps://modernaesthetics.com/news/endymeds-us-subsidiary-taps-bill-scott-as-new-president/2473215/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- Aquavit's Neurotoxin Submitted to FDAhttps://modernaesthetics.com/news/aquavits-neurotoxin-submitted-to-fda/2473213/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Cynosure and Jeisys Medical Japan Expand Partnershiphttps://modernaesthetics.com/news/cynosure-and-jeisys-medical-japan-expand-partnership/2473209/Cynosure LLC’s subsidiary Cynosure KK has entered into a distribution partnership with Jeisys Medical KK, a subsidiary of Jeisys Medical Inc. in Japan. Under the terms of the agreement, Jeisys Medical will have exclusive distribution rights for products within Cynosure&
- Endo Launches New Consumer Campaign for Qwohttps://modernaesthetics.com/news/endo-launches-new-consumer-campaign-for-qwo/2473202/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in Jul
- FDA Approves Mentor MemoryGel BOOST Breast Implanthttps://modernaesthetics.com/news/fda-approves-mentor-memorygel-boost-breast-implant/2473184/The Mentor® MemoryGel BOOST™ Breast Implant is now FDA approved for breast augmentation in women at least 22-years-old, and for women of all ages undergoing breast reconstruction. The product from Me
- Business News: $511M SPAC Merger Deal for Sunevahttps://modernaesthetics.com/news/business-news-511m-spac-merger-deal-for-suneva/2473182/Suneva Medical, Inc. and Viveon Health Acquisition Corp., a special purpose acquisition company (SPAC), are joining forces to form a regenerative aesthetics company. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE unde
- Does the "No Surprises Act" Apply to Aesthetic Services?https://modernaesthetics.com/news/does-the-no-surprises-act-apply-to-aesthetic-services/2473180/In a chat thread with colleagues on our mutual trade organizations' message board, there was a question about providing Good Faith Estimates (GFE) for aesthetic procedures under the No Surprises Act. I stated that I didn't think GFEs were required for aesthetic procedures, but a represent